ProfileJobs

iBio

Healthpharmaplatform

The iBio Technology has been validated by major industry players, as well as the Brazilian government, opening iBio’s doorway to the world market.
With extensive patent protection and proprietary know-how, iBio creates a high barrier to entry for competitors.
iBio’s global commercialization program, which was started in the favorable Brazilian market, is also licening the iBio Technology to key U.S. companies.
The iBio Technology platform is a proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins and has been validated across a wide range of applications in both vaccines and biotherapeutics.

Revenue(Q3, 2017)
$37 K
Market capitalization(2017-09-21)
$30.9 M
Company Growth (employees)
Type
Public
HQ
Newark, US
Founded
2008
Size (employees)
7 (est)
Website
ibioinc.com
iBio was founded in 2008 and is headquartered in Newark, US

iBio Office Locations

iBio has an office in Newark
Newark, US (HQ)
100 9 Innovation Way

iBio Data and Metrics

iBio Financial Metrics

iBio's revenue was reported to be $37 k in Q3, 2017
USD

Revenue (Q3, 2017)

37 k

EBIT (Q3, 2017)

(3.9 m)

Market capitalization (21-Sep-2017)

30.9 m

Cash (31-Mar-2017)

12.4 m
iBio's current market capitalization is $30.9 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

205 k1.9 m948 k

Revenue growth, %

803%(49%)

R&D expense

1.9 m3.5 m3.2 m

General and administrative expense

3.9 m5 m7.7 m
USDQ3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

819 k349 k160 k134 k379 k135 k75 k37 k

R&D expense

343 k1.2 m815 k551 k704 k1 m

General and administrative expense

951 k1.1 m1.2 m1.4 m1.7 m2.4 m2.5 m2.4 m2.8 m

Operating expense total

1.3 m2.2 m2 m2 m2.4 m3.5 m2.5 m2.4 m2.8 m
show all
USDFY, 2014FY, 2015FY, 2016

Cash

3.6 m9.5 m23 m

Inventories

118 k182 k264 k

Current Assets

3.9 m10.1 m23.9 m

PP&E

6 k13 k25.6 m
USDQ3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

4.3 m3.5 m8.1 m8.4 m6.7 m21.9 m20.1 m16.3 m12.4 m

Current Assets

5.5 m4.1 m9 m9.1 m7.2 m22.7 m20.5 m16.7 m13 m

PP&E

7 k20 k14 k10 k14 k25.8 m25.6 m25.5 m25.8 m

Total Assets

8.2 m6.7 m11.4 m11.4 m9.4 m50.7 m48.1 m44.2 m40.7 m
show all
USDFY, 2014FY, 2015FY, 2016

Net Income

(3.7 m)(6.6 m)(10.7 m)

Depreciation and Amortization

361 k363 k940 k

Inventories

97 k(64 k)(82 k)

Accounts Payable

56 k806 k(125 k)
USDQ3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(1.3 m)(1.4 m)(1.7 m)(1.8 m)(2.2 m)(3.6 m)

Accounts Payable

1.1 m516 k815 k1.3 m1.6 m979 k731 k1.4 m
show all
USDY, 2017

Revenue/Employee

5.3 k

Financial Leverage

3.1 x
Show all financial metrics

iBio Operating Metrics

FY, 2016

Patents Issued

67

Patents Pending

19
Show all operating metrics

iBio Market Value History

iBio Revenue Breakdown

Market Position of iBio

Competitors

Synergy Pharmaceuticals
Health - Public
Ayogo
Health - Private
Flamel Technologies
Health - Public
BioQ Pharma
Health - Private
Compare competitors

Traffic Overview of iBio

iBio News and Updates

October 24, 2016

Machine vision startup Chronocam raises $15 million from Intel Capital and others

Paris-based Chronocam has raised $15 million in a series B round led by Intel Capital to further develop and commercialise its machine vision sensors and expand into the US and Asia. The round was announced today at Intel Capital Global Summit. iBionext, Robert Bosch Venture Capital, 360 Capital, CE…

iBio Company Life and Culture

You may also be interested in